DARE Q3'26 Earnings: revenue estimate is 1.57M USD
Dare Bioscience (DARE) is scheduled to release Q3'26 earnings on November 05. Analysts expect revenue of 1.57M USD and EPS of (0.16) USD. The announcement is expected at 7:00 AM ET (12:00 PM UTC).
How this was made

The 30-second read
Why it matters
The earnings preview provides the first quantitative guidance for Q3'26, offering a baseline for traders to gauge surprise.
Market read
Limited to DARE; broader market impact minimal.
What to watch
Potential upcoming clinical trial data or partnership announcements not mentioned could swing sentiment.
Background
Dare Bioscience is a micro‑cap biotech listed on Nasdaq, primarily focused on gene‑editing technologies.
Ticker impact
Dare Bioscience announced its Q3'26 earnings release with revenue estimate of $1.57M and EPS of -$0.16, the first public disclosure of these figures.
potential volatility around the Nov 5 earnings release, likely pressure if results miss the modest estimate
The company is small and the forecast is low‑scale; traders may react to any deviation from the $1.57M revenue guide.
Market effects
Biotech sector may see slight attention but impact limited to DARE.
U.S. small‑cap market may experience minor volume around the release.
Low
Counterpoint
Given the tiny revenue forecast, a short position could profit if the market overreacts to the release.
Key entities
- CompanyDare Bioscience, Inc.
US‑listed biotech (ticker DARE) reporting Q3'26 earnings.